[(2R,3R,4R,5R)-3-benzoyloxy-5-(6-chloro-2-methylpurin-9-yl)-4-fluoro-4-methyloxolan-2-yl]methyl benzoate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: [(2R,3R,4R,5R)-3-benzoyloxy-5-(6-chloro-2-methylpurin-9-yl)-4-fluoro-4-methyloxolan-2-yl]methyl benzoate
• 化学式: C₂₆H₂₂ClFN₄O₅
• 分子量: 524.9
• InChiKey: SGHJMSAZTAWKGN-SHKCYZCESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
  申请人：ALIOS BIOPHARMA, INC.

  公开号：US20140179910A1

  公开（公告）日：2014-06-26

  Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

  本文公开了核苷酸类似物、合成核苷酸类似物的方法以及使用一个或多个核苷酸类似物治疗HCV感染等疾病和/或病况的方法。
• β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10000523B2

  公开（公告）日：2018-06-19

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  结构的化合物： 或其药学上可接受的盐或组合物，用于治疗感染或暴露于 HCV 病毒的宿主或本文更全面描述的其他疾病。
• β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10005811B2

  公开（公告）日：2018-06-26

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  结构的化合物： 或其药学上可接受的盐或组合物，用于治疗感染或暴露于 HCV 病毒的宿主或本文更全面描述的其他疾病。
• 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10946033B2

  公开（公告）日：2021-03-16

  The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.

  将所述化合物或其药学上可接受的盐或组合物用于治疗感染了除 HCV 以外的 RNA 病毒的宿主或本文更全面描述的其他疾病。
• BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20180030082A1

  公开（公告）日：2018-02-01

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.